RxDoctor Payments Data

Faizan Hafeez, MD

Neurology · Toledo, OHNPI 1386630432

Payments from drug & device makers

$336,576in general payments, 2019–2025

Across 1,707 payments — averaging $197.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$163K
  • Amgen$47K
  • Lilly USA, LLC$47K
  • Axsome Therapeutics, Inc.$28K
  • Biohaven Pharmaceuticals, Inc.$19K
  • Pfizer$13K
  • plus $19K from 42 others

What the payments were for

  • Consulting fees$9,3003%
  • Speaking & faculty fees$286,18085%
  • Grants$440%
  • Travel & lodging$14,0694%
  • Food & beverage$26,8798%
  • Education$1040%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$336,576 in reported general payments places this provider in the 90th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$310,179
Medicare patients
123
Services billed
27,988

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QuliptaAtogepant61$74,105
UbrelvyUbrogepant31$45,740
Aimovig AutoinjectorErenumab-Aooe44$39,715
Emgality PenGalcanezumab-Gnlm46$38,618
Ajovy AutoinjectorFremanezumab-Vfrm25$23,262
Sumatriptan Succinate114$10,575
RizatriptanRizatriptan Benzoate109$3,110
Naproxen Sodium76$2,952
Topiramate148$1,662
Ondansetron OdtOndansetron80$1,522
Verapamil SrVerapamil Hcl11$1,476
Pregabalin53$1,393
Carbamazepine ErCarbamazepine13$1,390
Tizanidine Hcl154$1,196
Nortriptyline Hcl84$959

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$163,354$119,84592 claims
Upsher-smith Laboratories LLCTopiramate$275$1,662148 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 702 neurology providers in Ohio.

Other neurology in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →